-
iPSC TechnologyContact Information
- Address: 8F, 55 Magokdong-ro, Gangseo-gu, Seoul, Republic of Korea(07802)
- Business Registration No.: 109-86-37282
- CEO: Choongseong Han
- Tel: +82-2-2088-8886
- Fax: +82-2-2088-8884
- E-mail: support@nexel.co.kr
-
- Home
- Service
- NeXST SVC Notice: Undefined variable: sub_code in /home/host/nexelshop/www/html/_skin/mdp/layout/inc_path.php on line 79
- Overview
NeXST SVC Overview
Cardiac Safety (Predicting proarrhythmic risk of investigational drugs)
Evaluating the effects of drugs on multi-ion channels in the cardiomyocytes.
Cardiomyocyte Viability has providing accurate prediction of proarrhythmic risk (TdP, Torsade de Pointes) of investigational drugs in accordance with the CiPA-initiated assessment method of new ICH Guideline.
* ISO17025 certified.
Applications:
* Proarrhythmic risk screening at early drug discovery (hit to lead).
* Optimal dose screening for preclinical study.
* Cardiac safety pharmacology study for IND filing of investigational drugs (after adoption of new ICH E14/S7B).
Cardiac contractility | Cardiomyocyte Viability
Providing real contractility measurement upon drug treatments from functional cardiomyocytes.
Applications:
* Screening the drug-induced cardiac contractile force changes (Investigational drugs from hit to preclinical stages)
* Efficacy and toxicity evaluation
Skeletal muscle contractility | Cardiomyocyte Viability
Providing clinically-relevant functional data by measuring real contractile force of 3D engineered skeletal muscle tissues.
Applications:
* Screening the drug-induced skeletal muscle contractile force changes (Investigational drugs from hit to preclinical stages)
* Efficacy and toxicity evaluation
Calcium transient
Providing surrogate evidence of intracellular calcium level changes upon drug treatment.
Applications:
* Screening the drug-induced calcium transient changes (Investigational drugs from hit to preclinical stages)
Lung toxicity
Human iPSC-derived AECs(Alveolar Epithelial Cells) are phenotypically and functionally resembled primary AECs and biologically relevant for pulmotoxic assessment.
Using the iPSC-derived AECs(Alveolar Epithelial Cells)-organoids for evaluation on functional effects of drugs is more clinically-relevant approach.
Applications:
* Potential lung toxicity screening at early drug discovery (hit to lead).
* Optimal dose screening for preclinical study.
Lung fibrosis
Providing anti-fibrotic effect of investigational drugs in TGF-β induced lung fibrosis organoid model.
Reference paper: Cell Death Discov. 2021 Mar 15;7(1):48)
Applications:
* Efficacy test of anti-fibrotic drugs at early drug discovery (hit to lead)
* Optimal dose screening for preclinical study.
Heart Failure assay | Cardiomyocyte Viability
NEXEL has developed self-organizing cardiac organoids (COs) from hiPSCs with a vascular network and extracellular matrix environment that resembles human heart tissue.
Providing drug-induced heart failure upon drug treatment in the organoid system (acute and chronic effects).
Applications:
* Proarrhythmic risk screening at early drug discovery (hit to lead).
* Optimal dose screening for preclinical study.
* Cardiac safety pharmacology study for IND filing of investigational drugs (after adoption of new ICH E14/S7B).
Cardiomyocyte Characterization | Cardiomyocyte Viability
Providing validation service for customer-developed cardiomyocytes (iPSC-derived or others).
Evaluating base electrical properties of the cardiomyocytes with drug responses against the reference drugs (3 ~ 4 drugs).
Applications:
* For cardiomyocytes developers in laboratories and industries.
Cardiac safety against the liver metabolite
!!Coming soon!!
| Assay Categories | Methods | Systems | Testing model | Data sets | Lead time |
|---|---|---|---|---|---|
| Cardiac safety (Predicting proarrhythmic risk of investigational drugs) | Electrical signal (Extracellular field potential) effects based evaluation | Axion Maestro / Nanion CardioExcyte 96 | Human iPSC-derived Cardiomyocytes (Cardiosight®-S) | FPDcF, Beat rate, Spike amplitude, Beat irregularity, Conductivity propagation (Axion Maestro only) | 1 - 2 months |
| Cardiac contractility | Impedance based evaluation | Nanion FLEXcyte 96 | Human iPSC-derived Cardiomyocytes (Cardiosight®-S) | Beat rate, Amplitude, Rising time, Falling time, Beat irregularity | 1 month |
| Skeletal muscle contractility | Magnetic force based evaluation | CuriBio Mantarray | 3D Engineered human muscle tissue | force frequency, rate of contraction / relaxation, time to max. twitch, max. twitch amplitude, full width at half max | 1 - 2 months |
| Calcium transient | Fluorescence image based evaluation | Molecular Device Microplate reader / NIS element software | Human iPSC-derived Cardiomyocytes (Cardiosight®-S) | Beat rate, peak to peak analysis, Amplitude | 1 - 2 months |
| Lung toxicity | PCR, Western Blot, ELISA | Varies | Human iPSC-derived lung organoids | Live and Dead, Changes in Lung functional markers, Changes in inflammatory factors | 2 months |
| Lung fibrosis | PCR, Western Blot | Varies | Fibrosis induced alveolar organoids (human iPSC-derived) | Fibrosis markers | 2 months |
| Heart Failure assay | Fluorescence image based evaluation Immunocytochemistry | NIS element software | Human iPSC-derived multicellular cardiac organoids | Beat rate, peak to peak analysis, Amplitude, fibrosis marker | 2 ~ 3 months |
| Cardiomyocyte Characterization | Baseline properties of iPSC-CM Electrophysiological effects upon reference drug treatment | Axion Maestro | Customer providing cardiomyocytes | Beat rate, FPDcF, Spike amplitude, Drug response | 1 ~ 2 months |
| Cardiac safety against the liver metabolites | coming soon | coming soon | coming soon | coming soon | TBD |